SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Supha Pharmachem Ltd

BSE: 539561 NSE: ISIN: INE549S01036
  |   Sector:  Miscellaneous   |   Industry:  Trading

Snapshot

Q.1 Which industry/sub-sector does Supha Pharmachem Ltd belong to?
Supha Pharmachem Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.
Q.2 Is Supha Pharmachem Ltd a good quality company?
Supha Pharmachem Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Supha Pharmachem Ltd undervalued or overvalued?
Supha Pharmachem Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Supha Pharmachem Ltd a good buy now?
Supha Pharmachem Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Supha Pharmachem Ltd?
Supha Pharmachem Ltd revenue growth is -94.5% for FY-2025 , which is below its 5 year CAGR of 138.4% , indicating slower growth.
Q.2 Gross Profit margin of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Gross profit margin which is the profit after deduction of direct costs, is 1.7% for FY-2025 , which is above its 5 year median of 1.3% , indicating increasing margins.
Q.3 Operating Profit Margin of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 0.24% for FY-2025 , which is below its 5 year median of 0.8% indicating decreasing margins.
Q.4 Net Profit Margin of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Net Profit Margin is 0.69% for FY-2025 , is in line with with its 5 year median of 0.69%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 1.7 1.3
Operating Profit Margin 0.24 0.8
Net Profit Margin 0.69 0.69
Q.5 Return on Asset of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Return on Asset is 0.09(x), which is below its 5 year historical median of 0.82(x), indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Return on equity is 3.55% for FY-2025 , which is below its historical median of 24.51%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Return on capital employed is 1.76% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Cash conversion cycle is 1038 , above its historical median of 21 , indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.13 2.61
ROE 3.55 24.51
ROCE 1.76 18.16
Cash Conversion Cycle 1038 21
Q.9 Debt to Equity ratio of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Debt-to-Equity ratio is 26.36 , which is above with the industry average of 0.03 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Supha Pharmachem Ltd?
Supha Pharmachem Ltd Debt to cash flow from operations is -1.06 , which is at a unhealthy level, indicating the business is not able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Supha Pharmachem Ltd?
Promoters hold 1.13% of the Supha Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Supha Pharmachem Ltd vs industry peers?
Supha Pharmachem Ltd revenue CAGR is 138.39% , compared to the industry median CAGR of 0% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 222.5 13.3
Gross Profit 3.8 0.4
Operating Profit 0.5 0
Net Profit 1.5 0.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.13 0.5
ROE 3.55 2.03
ROCE 1.76 3.6
Cash Conversion Cycle 1038.45 41

Valuation & price assessment

Q.1 Stock return of Supha Pharmachem Ltd over the last decade?
Over the last 9 years, the stock has delivered a CAGR of 0% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - 8.5% -60.8% -74.8%
Q.3 Valuation ratios of Supha Pharmachem Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - 7.01 21.75
Price to Book 0.37 4.37 1.55
Price to Sales 0.23 0.11 1.87
EV to EBITDA 1159.22 6.17 13.67

Check more companies

1. Aditya Infotech
2. Aegis Logistics
3. Redington
4. RRP Semiconductor
5. Honasa Consumer
6. Cello World
7. Lloyds Enterprises
8. MMTC
9. Jeena Sikho Life
10. SG Mart
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×